What types of patients are appropriate for maintenance therapy?
Maintenance therapy is treatment with a different agent that begins immediately after first-line chemotherapy in patients without disease progression. Tarceva monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. Results from two, multicenter, placebo-controlled, randomized, Phase III trials conducted in first-line patients with locally advanced or metastatic NSCLC showed no clinical benefit with the concurrent administration of Tarceva with platinum-based chemotherapy [carboplatin and paclitaxel or gemcitabine and cisplatin] and its use is not recommended in that setting.
Related Questions
- Does the abnormal signal-averaged electrocardiogram predict future appropriate therapy in patients with implantable cardioverter-defibrillators?
- Can we predict which patients with implantable cardioverter defibrillators receive appropriate shock therapy?
- Is Short-Duration Interferon Therapy Appropriate for Patients with Genotype 1 Hepatitis C?
